It is still too premature to conclude that IVIG had a disease-modifying effect, according to Dr. Relkin. "However, the shapes of those graphs are exactly what people model when they are predicting what a disease-modifying therapy would look like, which is that there is a divergence of slopes, which means that the curves widen as time goes on. I think we have to wait for the results of the phase III study before we can answer that question," he concluded.
Dr. Relkin disclosed that he receives research support from Baxter Healthcare, which supported the trial.